Cargando…

Cyclin-dependent kinase inhibitors in malignant hematopoiesis

The cell-cycle is a tightly orchestrated process where sequential steps guarantee cellular growth linked to a correct DNA replication. The entire cell division is controlled by cyclin-dependent kinases (CDKs). CDK activation is balanced by the activating cyclins and CDK inhibitors whose correct expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schirripa, Alessia, Sexl, Veronika, Kollmann, Karoline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403899/ https://www.ncbi.nlm.nih.gov/pubmed/36033505 http://dx.doi.org/10.3389/fonc.2022.916682

Ejemplares similares

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

STAT5A and STAT5B—Twins with Different Personalities in Hematopoiesis and Leukemia
por: Maurer, Barbara, et al.
Publicado: (2019)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
por: Lin, Z. Ping, et al.
Publicado: (2018)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
por: Wang, Bin, et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
por: Zuo, Fengli, et al.
Publicado: (2022)

The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis
por: Sun, Xiao-Jian, et al.
Publicado: (2015)

Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment
por: Asada, Noboru
Publicado: (2018)

c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
por: Kollmann, Karoline, et al.
Publicado: (2011)

The role of CDK6 in cancer
por: Nebenfuehr, Sofie, et al.
Publicado: (2020)

CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
por: Scheiblecker, Lisa, et al.
Publicado: (2020)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020)

Comprehensive Analysis of Role of Cyclin-Dependent Kinases Family Members in Colorectal Cancer
por: Guan, Liping, et al.
Publicado: (2022)

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
por: Merlini, Alessandra, et al.
Publicado: (2023)

The cyclin dependent kinase inhibitor p21(Cip1/Waf1) is a therapeutic target in high-risk neuroblastoma
por: Sorteberg, Agnes Luise, et al.
Publicado: (2022)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
por: Rottier, Pauline, et al.
Publicado: (2023)

The Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis
por: Wu, Xia, et al.
Publicado: (2022)

Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of Tetrastigma hemsleyanum
por: Wei, Chaoguang, et al.
Publicado: (2022)

Expression of cyclin-dependent kinase inhibitor p27kip1 in malignant lymphomas.
por: Oh, Y. H., et al.
Publicado: (2000)

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
por: Gagliano, Ambrogio, et al.
Publicado: (2021)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy
por: Zhao, Huijuan, et al.
Publicado: (2022)

Technical Advances in Single-Cell RNA Sequencing and Applications in Normal and Malignant Hematopoiesis
por: Huang, Xiang-tao, et al.
Publicado: (2018)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

P1412: UNCOUPLING INK4 PROTEINS FROM CDK4/CDK6 IN HEMATOPOIETIC STEM CELLS
por: Schirripa, A., et al.
Publicado: (2022)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)

Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?
por: Cumbo, Cosimo, et al.
Publicado: (2022)

Cyclin-Dependent Kinase 5 Regulatory Subunit Associated Protein 3: Potential Functions and Implications for Development and Disease
por: Sheng, Linna, et al.
Publicado: (2021)

Corrigendum: Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy
por: Zhao, Huijuan, et al.
Publicado: (2023)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
por: Richter, Anna, et al.
Publicado: (2021)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3317ig72r2o9c0303kbt23b2bg